Chip stocks fall with Nvidia after data center rev disappointment
Raanana, Israel - Polyrizon Ltd. (NASDAQ:PLRZ), a biotech firm in the development stage, has filed a divisional patent application in Israel for its Trap & Target (NYSE:TGT) (T&T) platform technology. This move, announced today, aims to protect the company’s advanced intranasal drug delivery system designed to improve medication efficacy by increasing residence time and contact with mucosal tissues.
The T&T technology focuses on enhancing the bioavailability of active pharmaceutical ingredients (APIs), offering a controlled release, and preventing dripping from the nasal cavity. It utilizes biodegradable components and is versatile enough to be compatible with various drug types, including small molecules and antibodies.
Polyrizon’s CEO Tomer Izraeli believes that the T&T platform could transform intranasal drug delivery, potentially improving efficacy and safety for a wide range of medications. The platform leverages the nasal cavity’s rich vascularization for both local and systemic drug delivery, which could be beneficial for treating respiratory conditions, central nervous system disorders, and other medical needs.
The divisional patent application complements Polyrizon’s recent U.S. patent application, which covers aspects of its two core technologies: Capture and Contain (C&C™) and T&T. The C&C platform is designed to form a barrier against airborne threats such as allergens and viruses by adhering to the nasal mucosa.
Polyrizon specializes in developing medical device hydrogels in the form of nasal sprays, which aim to create a barrier against viruses and allergens. The company is advancing its C&C hydrogel technology to enhance bioadhesion and retention for intranasal drug delivery.
This press release contains forward-looking statements regarding the company’s intellectual property protection efforts and the potential of its technologies to revolutionize respiratory health and drug delivery. However, there are no guarantees that any patent will be issued or, if issued, that it will be advantageous to the company. InvestingPro analysis highlights several risk factors, including high price volatility and weak gross profit margins. Subscribers to InvestingPro can access additional insights and metrics to better evaluate the company’s potential. These statements are based on current management expectations and are subject to risks and uncertainties that could cause actual results to differ materially.
The filing of this patent application represents Polyrizon’s ongoing commitment to securing its intellectual property and advancing its technology to address healthcare challenges. The information is based on a press release statement from Polyrizon Ltd.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.